Asthma
Conditions
Keywords
Infants, Exhaled Nitric Oxide, Asthma, Tobacco smoke exposure, environment
Brief summary
Background: It seems that in the infants and the young children, the increase of the Exhaled Nitric Oxide (eNO) is in connection with: (1) the risk of developing respiratory symptoms; (2) the risk of family and personal atopy; (3) the intensity of the respiratory symptoms; (4) the risk of passage of recurrent wheezing to asthma; (5) and contrary to the fact that the investigators noticed at the child's a positive relation with the environmental tobacco smoke Objective: the investigators objective is to bring to light that the rise of the eNO, a non invasive biomarker of the bronchial inflammation, would be a risk factor expected from passage of recurrent wheezing of the infant and the young child (of less than 36 months old) towards the asthma of the child.Methods: Once the diagnosis of recurrent wheezing established, the investigators estimate by questionnaire the severity of the asthma, the personal and familial atopy, the collection of the environmental data. After allergic exploration (skin tests and assay of serum total and specific IgE, complete blood count), the eNO is measured by an off-line tidal breathing method using a chemiluminescence NO analyzer. Annually, a questionnaire will be send to families to appreciate the persistence or the remission of the asthma. After a simple descriptive analysis of the population and a multifactorial descriptive analysis, the investigators shall look for the connections between the rise of the eNO and the various clinical, biological and environmental parameters known to influence the variations of this marker. Then the investigators shall select a set of explanatory variables for a multivariate analysis by a logistic regression step by step.
Detailed description
This study is a epidemiological observation study
Interventions
OTHERMeasure of the exhaled NO
The exhaled NO will be measure by chemiluminescence in current ventilation by an indirect method (off-line)
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Months to 36 Months
Healthy volunteers
No
Inclusion criteria
* Infant between 6 and 36 months * More than 3 wheezing episodes * Questionary and biological assessment for recurrent wheeze * Signature of the consent by 2 parents or by the only one of 2 parents (if this last one is the only present in the inclusion of the child)
Exclusion criteria
* Infant with respiratory disease in neonatal period * Infant with other obstructive pathology (cystic fibrosis, Primary Ciliary Dyskinesia,…) * Infant who have a respiratory infection less than 4 weeks * Infant with asthma exacerbation or who still have corticosteroid treatment * Infant without social security from their parents
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measure of exhaled nitric oxide at the beginning of the study and incidence of asthma symptoms after 3 years of follow up | 1 day |
Secondary
| Measure | Time frame |
|---|---|
| Atopic status with total and specific IgE levels and skin test, complete blood count | 1 day |
Countries
France
Outcome results
None listed